RecruitingPhase 2NCT04250064

A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma


Sponsor

Tata Memorial Centre

Enrollment

40 participants

Start Date

Feb 4, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

In this study, the investigators are testing improvement in survival outcomes in DIPG patients when stratified with MR perfusion score and treated with the said protocol. Newly diagnosed DIPG patients will undergo MRI perfusion study in addition to the usual MRI at diagnosis and will be stratified into hyperperfused or hypoperfused tumours. The hyperperfused patients will receive additional low dose Bevacizumab weekly with conventional standard radiotherapy. The hypo-perfused patients will receive ultra-low-dose radiotherapy fractionation equivalent to conventional RT biological dose.


Eligibility

Min Age: 3 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bevacizumab Injection and Ultra-low-dose RT for people with dipg. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBevacizumab Injection

Additional concurrent low-dose Bevacizumab with standard EBRT

RADIATIONUltra-low-dose RT

Ultra-low-dose EBRT instead of standard dose RT


Locations(1)

Tata Memorial Hospital

Mumbai, Maharashtra, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04250064


Related Trials